



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2012

Particular	3 Months Ended	Previous	Corresponding	Year to date figure		Year to date figure	Previous
	30-Sep-2012	3 Months Ended	3 Months ended	for Current year	for Previous year	for Previous year	Accounting year
		30-Jun-2012	30-Sep-2011	30-Sept-2012 (Six Months)	30/09/2011 (12 Months)	30/09/2011 (12 Months)	31-Mar-2012 (18 Months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from operations							
(a) Net Sales/Income from operations (Net of excise duty)	2292.05	1979.80	2301.40	4271.85	9529.64	9529.64	13419.27
(b) Other Operating Income	104.35	142.16	102.66	246.51	368.82	368.82	561.90
Total income from operations (net)	2,396.40	2,121.96	2404.06	4,518.36	9898.46	9898.46	13981.17
2 Expenses							
(a) Cost of Materials Consumed	1115.66	927.89	1294.66	2,043.55	4564.75	4564.75	6744.15
(b) Purchase of traded goods	375.64	226.18	378.77	601.82	2217.50	2217.50	2687.58
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	111.60	59.83	-78.72	171.43	-139.32	-139.32	-172.13
(d) Employee benefits expense	252.95	265.15	262.42	518.10	1161.14	1161.14	1687.22
(e) Depreciation and amortisation expense	82.00	78.01	92.46	160.01	359.55	359.55	545.89
(f) Other expenses	336.38	365.26	336.10	701.64	1470.17	1470.17	2209.73
Total expenses	2274.23	1922.32	2285.69	4196.55	9633.79	9633.79	13702.44
3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)	122.17	199.64	118.37	321.81	264.67	264.67	278.73
4 Other Income	117.17	50.41	66.11	167.58	238.21	238.21	533.13
5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	239.34	250.05	184.48	489.39	502.88	502.88	811.86
6 Finance costs	372.11	368.33	407.35	740.44	1438.27	1438.27	2255.52
7 Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5+6)	-132.77	-118.28	-222.87	-251.05	-935.39	-935.39	-1443.66
8 Exceptional items (Net)							
a Profit on Sale of Fixed Assets	-	-	-	-	-	-	884.65
b Foreign Currency Monetary Item Translation	-	-	-	-	-138.24	-138.24	-
c Amortization of Expenses for restructuring	-12.48	-12.49	-	-24.97	-	-	-12.49
d Excess provision written back	-	62.21	-	62.21	-	-	-
Total Exceptional items (Net)	-12.48	49.72	-	37.24	-138.24	-138.24	872.16
9 Profit/(Loss) from Ordinary Activities before tax (7+8)	-145.25	-68.56	-222.87	-213.81	-1073.63	-1073.63	-571.50
10 Tax Expenses	-0.39	-	-	-0.39	-	-	-
11 Net Profit/(Loss) from Ordinary activities after tax (9+10)	-145.64	-68.56	-222.87	-214.20	-1073.63	-1073.63	-571.50
12 Extraordinary Item (net of tax expenses)	0.00	0.00	0.00	0.00	-	-	0.00
13 Net Profit/(Loss) for the period (11+12)	-145.64	-68.56	-222.87	-214.20	-1073.63	-1073.63	-571.50
14 Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00
15 Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	0	0	0	0	0	0	4645.68
16 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))							
(a) Basic	-0.67	-0.32	-1.03	-0.99	-4.98	-4.98	-2.65
(b) Diluted	-0.67	-0.32	-1.03	-0.99	-4.98	-4.98	-2.65
16 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))							
(a) Basic	-0.67	-0.32	-1.03	-0.99	-4.98	-4.98	-2.65
(b) Diluted	-0.67	-0.32	-1.03	-0.99	-4.98	-4.98	-2.65



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2012

Particular	3 Months Ended	Previous 3 Months Ended	Corresponding 3 Months ended in the Previous year	Year to date figure for Current year Ended	Year to date figure for Previous year Ended	Previous Accounting year Ended
	30-Sep-2012 (Unaudited)	30-Jun-2012 (Unaudited)	30-Sep-2011 (Unaudited)	30-Sept- 2012 (Six Months) (Unaudited)	30/09/2011 (12 Months) (Unaudited)	31-Mar-2012 (18 Months) (Audited)
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
Number of shares	16552735	16552735	16979735	16552735	16979735	16552735
percentage of shareholding	76.70	76.70	78.68	76.70	78.68	76.70
2 Promoters and promoter group - Shareholding						
a. Pledged / Encumbered						
- Numbers of Shares	4965615	4965615	4208615	4965615	4208615	4965615
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	98.77	98.77	91.49	98.77	91.49	98.77
- Percentage of shares (as a % of the total share capital of the company)	23.01	23.01	19.50	23.01	19.50	23.01
b. Non - encumbered						
- Number of shares	61650	61650	391650	61650	391650	61650
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	1.23	1.23	8.51	1.23	8.51	1.23
- Percentage of shares (as a % of the total share capital of the company)	0.29	0.29	1.82	0.29	1.82	0.29
B						
PARTICULARS						
INVESTOR COMPLAINTS		3 Month Ended				
Pending at the beginning of the quarter		-				
Received during the quarter		-				
Disposed of during the quarter		-				
Remaining unresolved at the end of the quarter		-				



Notes:

1. The above results were duly considered by the Audit Committee on 12th November, 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12th November, 2012.
2. During the Quarter the Company has charged Rs.19.14 lacs being depreciation on revalued assets.
3. During the Quarter, the Company has capitalised interest of Rs.15.29 lacs towards the Term Loan for Tarapur Upgradation and Rs.27.43 lacs towards pending allocation to Intangible Assets.
4. The Company's factory at Tarapur is under upgradation. In view of this the production has been suspended.
5. The Company has one Single Segment "Pharmaceuticals".
6. Previous periods figures have been regrouped/rearranged wherever necessary.

For LYKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Mumbai
12-Nov-12



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

Standalone statement of Assets and Liabilities

(Rs.in lakhs)

Particulars		As at Current half	As at Previous year
		year ended 30 Sept, 2012	ended 31 March, 2012
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,266.57	2,266.57
	(b) Reserves and Surplus	4,909.78	5,155.13
	Sub-Total -Shareholders' Fund	7,176.35	7,421.70
2	Non-Current Liabilities		
	(a) Long-Term Borrowings	6,035.09	5,112.26
	(b) Other Long-Term Liabilities	87.98	87.88
	(c) Long-Term Provisions	278.45	260.15
	Sub -Total -Non -Current liabilities	6,401.52	5,460.29
3	Current Liabilities		
	(a) Short-Term Borrowings	4,675.56	4,180.14
	(b) Trade Payables	3,353.83	4,333.05
	(c) Other Current Liabilities	2,165.48	2,454.72
	(d) Short-Term Provisions	76.28	68.53
	Sub -Total -Current liabilities	10,271.15	11,036.44
	TOTAL-EQUITY AND LIABILITIES	23,849.02	23,918.43
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	8,182.82	8,377.34
	(ii) Capital Work-in-Progress	1,143.01	1,082.49
	(iii) Intangible assets under development	962.86	800.05
		10,288.69	10,259.88
	(b) Non-Current Investments	2,022.36	2,021.35
	(c) Long-Term Loans and Advances	1,774.95	1,754.95
	Sub -Total -Non-Current assets	14,086.00	14,036.18



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

Standalone statement of Assets and Liabilities

(Rs.in lakhs)

Particulars	As at Current half year ended 30 Sept, 2012	As at Previous year ended 31 March, 2012
	Unaudited	Audited
2 Current Assets		
(a) Current Investments	-	1.00
(b) Inventories	1,288.25	1,496.79
(c) Trade Receivables	5,335.32	4,949.76
(d) Cash and Cash Equivalents	638.48	182.36
(e) Short-Term Loans and Advances	2,362.18	3,113.55
(f) Other Current Assets	138.79	138.79
Sub -Total -Current assets	9,763.02	9,882.25
TOTAL-ASSETS	23,849.02	23,918.43

FOR LYKA LABS LIMITED

(N.I.Gandhi)
(Chairman & Managing Director)



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49
Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2012

(Rs.in Lacs)

Particulars	3 Months Ended 30-Sept-2012	3 Months Ended 30-June-2012	Corresponding 3 months ended in the previous year 30-Sept-2011	Year To Date Figures For Current period ended 30-Sept-2012 (6 months)	Year to date figure for the year ended 30-Sept-2011 (12 months)	Previous Accounting year ended 31- March-2012 (18 months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from operations						
(a) Net Sales/Income from operations (Net of excise duty)	3,278.77	3,012.71	2,611.68	6291.48	11420.37	16185.21
(b) Other Operating Income	129.32	163.14	127.01	292.46	501.53	808.21
Total income from operations (net)	3,408.09	3,175.85	2738.69	6,583.94	11921.90	16,993.42
2 Expenses						
(a) Cost of Materials Consumed	1,115.66	927.89	1,294.66	2043.55	4564.75	6744.15
(b) Purchase of traded goods	696.49	659.26	534.61	1355.75	2944.28	3670.50
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	82.71	29.07	-99.68	111.78	-160.28	-194.96
(d) Employee benefits expense	298.94	298.83	305.07	597.77	1299.26	1967.02
(e) Depreciation and amortisation expense	127.64	123.54	146.26	251.18	572.11	864.90
(f) Other expenses	571.13	579.55	485.41	1150.68	2256.86	3301.88
Total expenses	2,892.57	2,618.14	2,666.33	5510.71	11476.98	16353.49
3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)	515.52	557.71	72.36	1073.23	444.92	639.93
4 Other Income	119.29	62.73	36.30	182.02	207.67	409.05
5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	634.81	620.44	108.66	1255.25	652.59	1048.98
6 Finance costs	481.45	487.09	515.16	968.54	1898.71	3035.87
7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5+6)	153.36	133.35	-406.50	286.71	-1246.12	-1986.89
8 Exceptional Items (Net)						
a PROFIT ON SALE OF FIXED ASSETS						
b Foreign Currency Monetary Item Translation					-158.64	
c Amortization of Expenses for restructuring	-12.48	-12.49	-	-24.97	-	-12.49
d Excess provision written back	-	62.21	-	62.21	-	1246.71
8 Total Exceptional items (Net)	-12.48	49.72	-	37.24	-158.64	1234.22
(ii) Provision for Taxation of earlier years	-0.39	-	-	-0.39	-	-
9 Profit/(Loss) from Ordinary Activities before tax (7+8)	140.49	183.07	-406.50	323.56	-1404.76	-752.67
10 Tax Expenses	-	-	-	-	-	-
11 Net Profit/(Loss) from Ordinary activities after tax (9+10)	140.49	183.07	-406.50	323.56	-1404.76	-752.67
12 Extraordinary Item (net of tax expenses)	-	-	-	-	-	-
13 Net Profit/(Loss) for the period (11+12)	140.49	183.07	-406.50	323.56	-1404.76	-752.67
14 Share of Profit/(Loss) of associates	-	-	-	-	-	-
15 Minority interest	99.04	87.99	-115.68	187.04	-115.16	-63.01



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2012

Particulars	(Rs.in Lacs)					
	3 Months Ended 30-Sept-2012 (Unaudited)	3 Months Ended 30-June-2012 (Unaudited)	Corresponding 3 months ended in the previous year 30-Sept-2011 (Unaudited)	Year To Date Figures For Current period ended 30-Sept-2012 (6 months) (Unaudited)	Year to date figure for the year ended 30-Sept-2011 (12 months) (Unaudited)	Previous Accounting year ended 31-March-2012 (18 months) (Audited)
16 Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	41.45	95.08	-290.82	136.52	-1289.60	-689.66
17 Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00
18 Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year	-	-	-	-	-	3,525.69
19 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)						
(a) Basic	0.19	0.85	-1.88	0.60	-6.51	3.25
(b) Diluted	0.19	0.85	-1.88	0.60	-6.51	3.25
19 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)						
(a) Basic	0.19	0.85	-1.88	0.60	-6.51	3.25
(b) Diluted	0.19	0.85	-1.88	0.60	-6.51	3.25
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of shares	16552735	16552735	16979735	16552735	16979735	16552735
- Percentage of shareholding	76.70	76.70	78.68	76.70	78.68	76.70
2 Promoters and promoter group - Shareholding						
a. Pledged / Encumbered						
- Numbers of Shares	4965615	4965615	4208615	4965615	4208615	4965615
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	98.77	98.77	91.49	98.77	91.49	98.77
- Percentage of shares (as a % of the total share capital of the company)	23.01	23.01	19.50	23.01	19.50	23.01
b. Non - encumbered						
- Number of shares	61650	61650	391,650	61650	391650	61650
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	1.23	1.23	8.51	1.23	8.51	1.23
- Percentage of shares (as a % of the total share capital of the company)	0.29	0.29	1.82	0.29	1.82	0.29

	PARTICULARS	3 Month ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-



Notes:

1. The above results were duly considered by the Audit Committee on 12th November, 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12th November, 2012.
2. Limited Review financial results for the quarter ended 30/09/2012 have been consolidated with that of Lyka BDR International Ltd., as approved by their Board.
3. During the quarter Company has charged Rs.19.14 lacs being depreciation on revalued assets.
4. During the Quarter, the Company has capitalised interest of Rs.15.29 lacs towards the Term Loan for Tarapur Upgradation and Rs.27.43 lacs towards pending allocation to Intangible Assets.
5. The Company's factory at Tarapur is under upgradation. In view of this, the production has been suspended.
6. The Company has one Single Segment "Pharmaceuticals".
7. Previous periods figures have been regrouped/rearranged wherever necessary.

For L YKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Mumbai
12-Nov-12.



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti-Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

Consolidated statement of Assets and Liabilities

Particulars	As at Current half year ended 30 Sept, 2012	As at Previous year ended 31 March, 2012
	Unaudited	Audited
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	2,266.57	2,266.57
(b) Reserves and Surplus	5,171.98	5,121.22
Sub-Total -Shareholders' Fund	7,438.55	7,387.79
2 Minority Interest	356.56	169.52
3 Non-Current Liabilities		
(a) Long-Term Borrowings	6,035.09	5,112.26
(b) Other Long-Term Liabilities	87.98	87.88
(c) Long-Term Provisions	303.30	277.44
Sub -Total -Non -Current liabilities	6,426.37	5,477.58
4 Current Liabilities		
(a) Short-Term Borrowings	7,878.61	7,014.70
(b) Trade Payables	3,692.24	4,507.45
(c) Other Current Liabilities	3,428.91	3,620.58
(d) Short-Term Provisions	82.96	75.14
Sub -Total -Current liabilities	15,082.72	15,217.87
TOTAL-EQUITY AND LIABILITIES	29,304.20	28,252.76
B ASSETS		
1 Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	12,326.60	12,666.63
(ii) Capital Work-in-Progress	1,143.01	1,082.49
(iii) Intangible assets under development	962.86	800.05
(b) Non-Current Investments	14,432.47	14,549.17
(c) Long-Term Loans and Advances	553.32	552.30
(d) Other Non Current Assets	1,274.95	1,348.31
	253.30	-
Sub -Total -Non-Current assets	16,514.04	16,449.78



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

Consolidated statement of Assets and Liabilities

Particulars	As at Current half year ended 30 Sept, 2012	As at Previous year ended 31 March, 2012
	Unaudited	Audited
2 Current Assets		
(a) Current Investments	-	1.00
(b) Inventories	1,458.89	1,607.83
(c) Trade Receivables	7,432.08	6,102.79
(d) Cash and Cash Equivalents	650.43	219.02
(e) Short-Term Loans and Advances	2,499.34	3,182.32
(f) Other Current Assets	749.42	690.02
Sub -Total -Current assets	12,790.16	11,802.98
TOTAL-ASSETS	29,304.20	28,252.76

FOR LYKA LABS LIMITED


(N.I. Gandhi)
(Chairman & Managing Director)